108.86 USD
↘ 1.06 (0.96%)LIVE (AS OF 10:30 AM EDT)
Dianthus Therapeutics, Inc. Common Stock
DNTHNASDAQ • USD
Market: OPEN
Dianthus Therapeutics, Inc. Common Stock (DNTH) trades at $108.86 per share. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 2/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Aug 6, 2026.
Open?$111.60
High?$113.06
Low?$106.05
Prev. Close?$109.92
Volume?68.9K
Avg. Volume?1.1M
VWAP?$109.77
Rel. Volume?0.06x
Bid / Ask
Bid?$92.81 × 100
Ask?$124.55 × 100
Spread?$31.74
Midpoint?$108.68
Valuation & Ratios
Market Cap?6.1B
Shares Out?54.7M
Float?51.2M
Float %?93.7%
P/E Ratio?N/A
P/B Ratio?5.25
EPS?-$3.44
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Employees
92
Market Cap
6.3B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2023-09-12
Address
7 TIMES SQUARE
NEW YORK, NY 10036
Phone: 929-999-4055
NEW YORK, NY 10036
Phone: 929-999-4055
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?100
Momentum?48
Short Sent.?25
Piotroski F-Score?2/9Weak
Altman Z-Score?89.21Safe
Confidence?55%Low
Short InterestHigh
Short % of Float?18.00%High
Short Interest?9.2M
Days to Cover?8.9
Free Float51.2M
Avg Daily Volume1.0M
Settlement Date2026-07-15
Financial Health
Current Ratio?26.10Strong
Quick Ratio?26.10Strong
Cash Ratio?3.21Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?5.25FAIR▾
Peers100
S&P35
P/S?3,229.15HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-27.7CHEAP▾
S&P97
EV/Sales?3,171.09HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-16.4%WEAK▾
S&P8
ROA?-15.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-155709000
Enterprise Value?$6.0B
Fundamentals ratios updated end of day